Form 4: Novavax Director David M. Mott Acquires Equity Compensation

Novavax Inc. Director David M. Mott has acquired 28,326 stock options and 18,884 restricted stock units (RSUs) as part of his compensation, aligning his interests with shareholders.

Summary

• David M. Mott, a Director of Novavax Inc. (NVAX), acquired 28,326 stock options and 18,884 Restricted Stock Units (RSUs) on June 20, 2025.
• The stock options have an exercise price of $6.42 per share and expire on June 20, 2035.
• The RSUs represent a contingent right to receive one share of Novavax common stock for each unit, with a price of $0.
• Both the stock options and RSUs were granted on June 20, 2024, and vested 100% on the first anniversary of that grant date, which is June 20, 2025, subject to continued service on the Company's Board of Directors.
• Following these transactions, Mr. Mott beneficially owns 28,326 stock options and 18,884 RSUs directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine SEC Form 4 filing reporting director compensation, which is a standard corporate governance practice and does not inherently indicate positive or negative company performance.

Positives

• The acquisition of stock options and RSUs by a director aligns their financial interests with those of the company's shareholders, incentivizing long-term performance.
• The compensation structure, including equity grants, is a standard practice for attracting and retaining experienced board members.

Future Outlook

The vesting of these equity awards is contingent upon the director's continued service on the Board of Directors, indicating an expectation of ongoing commitment.

Industry Context

The granting of equity compensation, such as stock options and restricted stock units, to board members is a common practice across various industries, including the biotechnology and pharmaceutical sectors, to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The structure of equity compensation, including stock options and RSUs with vesting periods tied to continued service, is a standard practice for director compensation in publicly traded companies, particularly within the life sciences sector.
• The specific number of units and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this filing does not provide comparative data.

Corporate Governance

Related Party Transactions

• The acquisition of stock options and Restricted Stock Units by David M. Mott, a Director of Novavax Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The issuance of new equity (upon exercise of options or conversion of RSUs) could lead to minor dilution, but the intent is to align director interests with shareholder value creation.
• Director (David M. Mott): Receives significant equity compensation, incentivizing long-term commitment and performance.

Next Steps

• Continued service of David M. Mott on the Novavax Board of Directors to maintain beneficial ownership of the vested equity.

Key Dates

Keywords

Novavax, NVAX, SEC Form 4, Insider Transaction, Director Compensation, Stock Options, Restricted Stock Units, Equity Compensation, Corporate Governance